Routine

Urinary incontinence

Incontinence · Gynaecology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Female urinary incontinence is categorised mainly as stress, urgency or mixed. Conservative measures (pelvic floor training, bladder retraining) are first-line, with drug and surgical options reserved for those who do not respond.

Red flags

  • Visible haematuria (needs urgent urology referral)
  • Recurrent urinary tract infection
  • Palpable bladder/retention
  • Pelvic mass
  • Suspected fistula (continuous leakage after surgery or obstetric injury)

Assessment

Differential diagnosis

  • Stress urinary incontinence
  • Urgency incontinence (overactive bladder)
  • Mixed incontinence
  • Overflow incontinence (retention)
  • Fistula
  • Urinary tract infection

Investigations

  • Urinalysis and culture to exclude infection
  • Bladder diary over at least 3 days
  • Post-void residual volume assessment
  • Assessment of pelvic floor and prolapse on examination
  • Urodynamics before surgery or when the diagnosis is unclear
  • Symptom and quality-of-life questionnaires

Management

  • Categorise incontinence by history and bladder diary
  • Exclude infection, retention and significant prolapse
  • Advise lifestyle measures: weight loss, caffeine reduction and fluid management
  • Offer supervised pelvic floor muscle training for at least 3 months as first-line for stress incontinence
  • Offer bladder retraining as first-line for urgency incontinence
  • Add antimuscarinic or beta-3 agonist drugs for persistent overactive bladder
  • Consider duloxetine for stress incontinence where surgery is declined or unsuitable
  • Refer for specialist and surgical options if conservative measures fail
  • Review and manage treatment side effects, especially in older women

Drugs & doses

Oxybutynin, tolterodine or solifenacin (antimuscarinics) for overactive bladder
Mirabegron (beta-3 agonist) as an alternative, useful where anticholinergic load is a concern
Duloxetine 40 mg PO twice daily for stress incontinence (second-line)
Vaginal oestrogen for urogenital atrophy in postmenopausal women

Disposition

Manage conservatively in primary care; refer to urogynaecology for refractory symptoms, diagnostic uncertainty, or surgical consideration, and urology for haematuria.

Complications & pitfalls

  • Social isolation and reduced quality of life
  • Skin breakdown
  • Recurrent infection
  • Anticholinergic side effects, including cognitive effects in older women
  • Surgical complications (mesh-related issues)

Exam pearls

  • Supervised pelvic floor training works and should be tried for at least 3 months before surgery
  • Mirabegron avoids the anticholinergic burden of antimuscarinics in frail or older women
  • Visible haematuria mandates urgent referral to exclude malignancy
  • Continuous leakage after pelvic or obstetric surgery suggests a fistula

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.